pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,802 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1853Endpoints1442Fierce Biotech760BioSpace746BioPharma Dive544raps249onclive165fda recalls
therapy area
allOncology12828Rare Disease3326Immunology2981Cardiology2845Hematology2286Pulmonology2231Vaccines
  • White House withdraws Heidi Overton’s FDA nomination hours before Senate vote
    The White House has reportedly withdrawn the nomination of Dr. Heidi Overton, who was slated to become the FDA’s next commissioner, just hours before the Senate HELP Committee was set to vote. Ove…
    Fierce Biotech · 17h agoRegulatoryNegative↗ source
  • GSK receives accelerated FDA approval for oral lung cancer drug neladalkib
    GSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
    Endpoints · 17h agoApprovalPositive↗ source
← prev
page 2 of 153
next →
118
fda medwatch114
globenewswire health73
fda press61
1844
Psychiatry & CNS1229
Ophthalmology1129
Endocrinology & Metabolism806
Pain789
Nephrology782
  • AriBio's AR1001 shows 31% slower cognitive decline in monotherapy Phase 3 trial
    AriBio presented data at the 2026 Clinical Trials on Alzheimer's Disease conference indicating its candidate AR1001 slowed cognitive decline compared with placebo in patients not taking other Alzhe…
    BioSpace · 23h agoPositive readoutPositive↗ source
  • Beren Therapeutics secures FDA approval for Lembaz to treat infantile-onset Niemann-Pick disease type C
    Beren Therapeutics announced that the U.S. Food and Drug Administration has approved its drug Lembaz for the treatment of infantile‑onset Niemann‑Pick disease type C, a rare and severe pediatric co…
    Endpoints · 17h agoApprovalPositive↗ source
  • Sellas Life Sciences reports Phase 3 success for AML vaccine galinpepimut-S
    Sellas Life Sciences announced on Tuesday that its experimental cancer vaccine achieved a positive outcome in a Phase 3 study. The trial enrolled patients with a specific form of acute myeloid leu…
    Endpoints · 19h agoPositive readoutPositive↗ source
  • FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefit
    The FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…
    Fierce Biotech · 21h agoCRLNegative↗ source
  • Genetix Biotherapeutics reports $327M YTD sales and projects $500M full-year revenue, marking profitability
    Genetix Biotherapeutics, the former bluebird bio, announced that it has become profitable, reporting $327 million in U.S. net sales year‑to‑date and forecasting total 2026 sales of about $500 milli…
    BioSpace · 1d agoEarningsPositive↗ source
  • FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimab
    The U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…
    Endpoints · 17h agoRegulatoryNegative↗ source
  • FDA unveils Global Reliance Disclosure Program to speed international drug approvals
    The FDA announced the Global Reliance Disclosure Program (GRDP) on November 17, 2026, describing it as a new effort to share its drug and biologic approval packages with other health authorities.…
    fda press · 17h agoRegulatoryPositive↗ source
  • AI drugmaker Isomorphic Labs raises $5 billion in Series C round
    Isomorphic Labs, an Alphabet spinout that applies artificial intelligence to drug discovery, announced a $5 billion Series C financing. The round was led by Greenoaks and Sequoia Capital, with Alp…
    BioPharma Dive · 21h agoDealPositive↗ source
  • Priavoid's Alzheimer's pill PRI-002 fails Phase 2 trial
    German biotech startup Priavoid has been developing a small-molecule pill intended to break up amyloid protein clumps in the brains of Alzheimer's patients. The company recently reported results f…
    Endpoints · 22h agoNegative readoutNegative↗ source
  • Vertex renews partnership with Genomics in up to $220 million, four-year extension
    Vertex Pharmaceuticals has extended its collaboration with sequencing specialist Genomics, signing a new agreement that can be worth up to $220 million. The extension adds four more years to the e…
    Fierce Biotech · 22h agoDealPositive↗ source
  • Mount Sinai researchers map enzyme structure linked to rare metabolic disorder GA1
    Researchers at Icahn School of Medicine at Mount Sinai have determined the crystal structure of an upstream enzyme involved in glutaric aciduria type 1 (GA1), a rare neuro‑metabolic disease. GA1 r…
    Fierce Biotech · 1d agoPositive readoutPositive↗ source
  • Marrow Therapeutics raises $173M to develop bone-marrow-targeted gene therapies for blood disorders
    Marrow Therapeutics announced a $173 million financing round, combining a $53 million Series A led by founder Scion Life Sciences and venBio with a $120 million Series B led by OrbiMed. The compan…
    BioSpace · 1d agoDealPositive↗ source
  • Marrow Therapeutics secures $173 million to advance siRNA therapy for sickle cell, targeting CRISPR competition
    Marrow Therapeutics announced a $173 million financing round to fund development of its siRNA drug aimed at treating sickle cell disease. The funding comes after FDA approval of two gene therapies…
    Endpoints · 1d agoDealPositive↗ source
  • Medtronic to acquire Contego Medical for over $380 million to expand carotid and peripheral vascular portfolio
    Medtronic announced it will purchase Contego Medical, a developer of carotid artery disease and peripheral thrombectomy technologies. The deal is valued at more than $380 million, with potential a…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Kyntra Bio drops mid-stage prostate cancer ADC program after failing efficacy criteria
    Kyntra Bio announced in its third-quarter earnings release that it is terminating the phase 2 study of its CD46-targeting antibody-drug conjugate FG-3246 in metastatic castration-resistant prostate…
    Fierce Biotech · 1d agoNegative↗ source
  • Panelists say 2027 could be Europe’s breakout year for biotech investment
    Fierce Biotech hosted a panel during its London Life Sciences Week to debate whether Europe can boost its biopharma investment in 2027. The discussion came a day after venture capital firm Sofinno…
    Fierce Biotech · 1d agoPositive↗ source
  • EU regulators and industry discuss streamlining combination product oversight at summit
    At the AFDO/RAPS Combination Products Summit, a panel of European regulators and industry representatives met to explore ways to simplify the regulatory pathway for combination products in the EU.…
    raps · 1d agoRegulatoryNeutral↗ source
  • Heidi Overton faces Senate committee vote on FDA commissioner nomination amid uncertainty
    The Trump administration’s nominee for FDA commissioner, Heidi Overton, is scheduled for a vote before the Senate health, education, labor and pensions committee. Lawmakers have not indicated a cl…
    Endpoints · 17h agoRegulatoryNeutral↗ source
  • Cognito Therapeutics readies FDA submission for Alzheimer's light-and-sound headset after trial miss
    Cognito Therapeutics is preparing an FDA submission for its Spectris device, a headset that delivers patterned light and sound therapy aimed at treating Alzheimer's disease. The technology builds o…
    Endpoints · 21h agoRegulatoryNeutral↗ source
  • Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemia
    Marrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…
    BioPharma Dive · 1d agoDealPositive↗ source
  • FDA releases new manual outlining clinical pharmacology review practices for NDAs and BLAs
    The U.S. Food and Drug Administration’s Office of Translational Sciences and Office of Clinical Pharmacology have issued a new manual of procedures and policies (MAPP).\n\nThe document sets out goo…
    raps · 1d agoRegulatoryNeutral↗ source
  • Novo revamps NovoCare DTC platform as Roche’s Gazyva receives renewed approval
    Novo announced a revamp of its direct-to-consumer service, NovoCare, describing it as a reimagined platform for patients. The update includes a refreshed user interface and expanded resources aime…
    Endpoints · 22h agoRegulatoryNeutral↗ source
  • b.well introduces safety tools for AI health chatbots
    b.well, a startup focusing on patient data, announced new tools aimed at improving safety of AI-driven health chatbots. The tools address concerns that large language models may mishandle personal…
    Endpoints · 23h agoPositive↗ source